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INTRODUCTION
Both solid and hematological malignancies are known 
to cause pericardial effusions. The hematological 
malignancies that most often cause pericardial effusion 
are leukemias, Non-Hodgkin’s lymphomas, and 
Hodgkin’s lymphomas.1 Patients can also develop 
pericardial effusions from cancer-related causes, such 
as chemotherapy, immunotherapy, radiation, or 
infection.2 Although it has been reported in the literature 
(approximately 27 cases between 1970 to 2019), 
malignant pericardial effusion from multiple myeloma is 
relatively uncommon.3,4 In addition, a rare but known 
complication of poorly controlled multiple myeloma is 
hyperviscosity syndrome, which typically presents as 
spontaneous hemorrhage of the mucosal membranes, 
headaches or neurological symptoms. We present a 
case of a patient with multiple myeloma who was found 
to have a pericardial effusion with tamponade that was 
also complicated by hyperviscosity syndrome. 
CASE PRESENTATION
History of Present Illness 
A 78-year old African American female with a past 
medical history of IgA Kappa Multiple Myeloma was 
transferred to the Cardiovascular Intensive Care Unit 
(CVICU) at Thomas Jefferson University Hospital (TJUH) 
after being diagnosed with a pericardial effusion with 
tamponade physiology at an outside hospital. 
The patient was diagnosed with multiple myeloma 3 
years prior on a left maxillary biopsy revealing a 
plasmacytoma. Due to medical complications, multiple 
hospitalizations, poor follow up, and intermittent refusal 
of chemotherapy, the patient never achieved remission 
of her malignancy. Due to continued progression of her 
disease, she was started on Melphalan /methylpred-
nisolone therapy and had finished 5 cycles. 
CARDIOLOGY
Figure 1. (A) RA diastolic collapse showing evidence of early tamponade. 
(B) Plethoric IVC from a subcostal view. (C) Circumferential shot from a 
subcostal view to show the extent of the pericardial effusion. 
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The patient was in her usual state of health until one 
week prior to presentation when she developed a cough 
and dyspnea on exertion. Since her symptoms 
progressed, she eventually went to the emergency 
department, where she was noted to have a pericardial 
effusion with signs of early tamponade physiology. She 
was transferred to the CVICU at TJUH for further care. 
Upon arrival to TJUH, the patient was tachycardic with 
heart rates in the 110s. A physical exam revealed 
jugular venous distension, normal S1 and S2 heart 
sounds, slight end expiratory wheezing throughout 
the lung fields, and a droopy right eyelid with nodules. 
A pulsus paradoxus was found to be 5 mm Hg and a 
bedside transthoracic echocardiogram (TTE) showed 
a circumferential pericardial effusion with a maximum 
size of 2.2 cm, brief right atrial diastolic collapse, and 
a non-compressible inferior vena cava concerning for 
early tamponade physiology. 
Hospital Course
Due to concern for tamponade, the patient received a 
pericardiocentesis with pericardial drain placement. 
Approximately 185 mL of sanguineous fluid was drained 
and sent to the lab for typical studies, including cytology 
plus flow cytometry. A repeat TTE showed trivial residual 
pericardial effusion with improved hemodynamic profile 
and resolution of tamponade. Pericardial fluid cytology 
and flow cytometry results showed evidence of plasma 
cells consistent with her underlying plasma cell myeloma.
Within a day of admission, the patient developed 
significant interval swelling of her right eye with 
ecchymosis of her medial upper eyelid and significant 
conjunctival hemorrhage. Due to subjective shortness of 
breath, a chest radiograph was done and showed the 
correct positioning of the pericardial drain. However, it 
incidentally showed new left sided pleural effusion. Given 
multiple sites of spontaneous hemorrhage and 
significantly elevated IgA levels (>4500), there was 
concern for hyperviscosity syndrome. Medical oncology 
was consulted and recommended urgent plasmapheresis, 
however, the patient initially refused conveying her wishes 
to pursue non-aggressive medical therapy. She was 
temporized with intravenous fluids and high-dose steroids. 
On day 7 of post-pericardial drain placement, there 
continued to be high output (>75mL/day) from the 
drain.  Given the increased risk of infection with 
prolonged drain placement and continued high output 
in the setting of hyperviscosity syndrome, the decision 
was made for doxycycline sclerotherapy to the 
pericardium with subsequent removal of the pericardial 
drain. Repeat TTE the following day showed only trivial 
pericardial effusion. 
Eventually, the patient consented to plasmapheresis, 
resulting in a downtrend of her IgA level. She received 
cytoreductive chemotherapy with cyclophosphamide 
and dexamethasone. The patient’s post-chemotherapy 
hospital course was complicated by paroxysmal 
supraventricular tachycardia, acute kidney injury, stress-
induced hyperglycemia requiring insulin therapy and 
febrile neutropenia from an unknown infectious source. 
These compl icat ions resolved with medica l 
management.
Prior to discharge, goals of care were readdressed. 
Although initially hesitant, the patient and her family 
ultimately decided to pursue aggressive treatment of 
her multiple myeloma. She was subsequently 
discharged to a sub-acute rehabilitation center after 
wh ich  she  under went  chemothe rapy  w i th 
daratumumab, pomalidomide, and dexamethasone. 
Two months after the patient’s initial presentation to 
the TJUH CVICU, the patient is doing well on her 
current chemotherapy regimen with down trending IgA 
levels. She has stable pleural effusions on chest x-ray. 
Repeat TTE’s show no evidence of pericardial effusion. 
She remains symptom free with no further medical 
complications. 
DISCUSSION & CONCLUSIONS
As stated previously, pericardial effusions secondary to 
multiple myeloma are very rare, seen in < 1% of cases.4 
Although in our case, the pericardial fluid was determined 
to be malignant in origin based on flow cytometry and 
cytology, the rapid re-accumulation of pericardial 
effusion almost a week after drain placement was 
presumed to be due to the spontaneous bleeding 
complications of hyperviscosity syndrome. The medical 
interventions were unique for this particular patient due 
to her preference of treatments. She was initially 
temporized with fluids and dexamethasone instead of 
immediately being started on plasmapheresis. 
Interestingly, temporizing measures did initially slow the 
rate of drain output. 
Despite stabilizing with steroids and fluids, the patient’s 
re-accumulating pericardial effusion necessitated 
management with sclerotherapy. Per review of literature, 
doxycycline sclerotherapy for recurrent pericardial 
effusions secondary to multiple myeloma has not been 
performed.4 The decision to attempt bedside doxycycline 
sclerotherapy highlights the role of shared-decision 
making between the patient, her family, cardiology, 
medical oncology, and thoracic surgery in order to 
respect the patient’s wishes to opt for minimally invasive 
treatment strategies. 
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Our case also explores the complicated relationship 
between management of plasma cell pericardial 
effusions and hyperviscosity syndrome, which may 
increase the risk of bleeding into the pericardium. When 
the patient is clinically and hemodynamically stable, and 
willing to receive plasmaphoresis, it is reasonable to treat 
the hyperviscosity syndrome prior to draining the 
pericardium to decrease the risk of post-intervention 
bleeding. However, when a patient presents with early 
signs of tamponade physiology or hemodynamic 
instability, then a pericardiocentesis could be considered 
and prioritized with simultaneous temporization of 
hyperviscosity syndrome utilizing high-dose steroids and 
fluids as we had done in this case. Finally, the case 
demonstrates that it is essential to intermittently revisit 
goals of care because our patient’s wishes evolved and 
molded her medical management. On-going discussions 
resulted in her changing her initial decision, and altering 
the course of her disease process. Our case of a patient 
with multiple myeloma presenting with malignant 
pericardial effusion as an extra-medullary manifestation 
of chemotherapy-refractory multiple myeloma is 
therefore unique from a clinical presentation, medical 
intervention, and a shared decision-making standpoint.
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